Anika Therapeutics Inc (NASDAQ:ANIK)’s Stock Is Sell After More Market Selling

June 18, 2018 - By Hazel Jackson

Anika Therapeutics, Inc. (NASDAQ:ANIK) Logo

Investors sentiment decreased to 1.24 in 2018 Q1. Its down 0.13, from 1.37 in 2017Q4. It fall, as 16 investors sold Anika Therapeutics, Inc. shares while 42 reduced holdings. 21 funds opened positions while 51 raised stakes. 12.25 million shares or 0.12% less from 12.26 million shares in 2017Q4 were reported.
Victory Cap Management accumulated 5,028 shares. First Manhattan owns 38,700 shares. Legal & General Gp Public Limited Company reported 0% of its portfolio in Anika Therapeutics, Inc. (NASDAQ:ANIK). Millennium Management Lc holds 43,415 shares. Eaton Vance owns 0% invested in Anika Therapeutics, Inc. (NASDAQ:ANIK) for 5,732 shares. Citigroup Inc has invested 0% of its portfolio in Anika Therapeutics, Inc. (NASDAQ:ANIK). Rhumbline Advisers has invested 0% in Anika Therapeutics, Inc. (NASDAQ:ANIK). Ameritas Prns Incorporated owns 1,142 shares. 31,335 were accumulated by Gotham Asset Mngmt Ltd Com. State Board Of Administration Of Florida Retirement has invested 0% of its portfolio in Anika Therapeutics, Inc. (NASDAQ:ANIK). Bokf Na has 11,135 shares for 0.02% of their portfolio. Creative Planning has invested 0% in Anika Therapeutics, Inc. (NASDAQ:ANIK). Us National Bank & Trust De, Minnesota-based fund reported 1,060 shares. Ny State Teachers Retirement reported 11,166 shares. Hl Financial Limited Com owns 0.01% invested in Anika Therapeutics, Inc. (NASDAQ:ANIK) for 5,829 shares.

The stock of Anika Therapeutics Inc (NASDAQ:ANIK) registered an increase of 2.92% in short interest. ANIK’s total short interest was 1.20M shares in June as published by FINRA. Its up 2.92% from 1.17M shares, reported previously. With 140,800 shares average volume, it will take short sellers 9 days to cover their ANIK’s short positions. The short interest to Anika Therapeutics Inc’s float is 8.36%.

The stock increased 0.63% or $0.28 during the last trading session, reaching $45.05. About 164,800 shares traded or 2.11% up from the average. Anika Therapeutics, Inc. (NASDAQ:ANIK) has declined 13.22% since June 18, 2017 and is downtrending. It has underperformed by 25.79% the S&P500.

Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company has market cap of $644.69 million. The firm develops, makes, and commercializes therapeutic products based on its proprietary hyaluronic acid technology. It has a 34.65 P/E ratio. The Company’s orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a woven gauze used as a bone graft wrap; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment.

Anika Therapeutics, Inc. (NASDAQ:ANIK) Ratings Coverage

Among 3 analysts covering Anika Therapeutics Inc (NASDAQ:ANIK), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Anika Therapeutics Inc had 4 analyst reports since December 28, 2017 according to SRatingsIntel. As per Friday, February 23, the company rating was downgraded by Barrington Research. The rating was upgraded by First Analysis to “Overweight” on Wednesday, January 24. Barrington Research upgraded the stock to “Outperform” rating in Friday, May 4 report.

More news for Anika Therapeutics, Inc. (NASDAQ:ANIK) were recently published by:, which released: “Anika Therapeutics (ANIK) Reports $30M Accelerated Share Buyback” on May 23, 2018.‘s article titled: “Analysts Remain Bullish on Flexion Therapeutics” and published on June 12, 2018 is yet another important article.

Anika Therapeutics, Inc. (NASDAQ:ANIK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.